1. How many melanoma patients currently undergoing treatment are BRAF+?
2. In the past 3 months, how many melanoma patients were treated with the following:
Bevacizumab
Cobimetinib
Dabrafenib
Dabrafenib AND Trametinib
Dacarbazine
Encorafenib AND Binimetinib
Ipilimumab
Ipilimumab AND Nivolumab
Nivolumab
Pembrolizumab
Trametinib
Vemurafenib
Vemurafenib AND Cobimetinib
Other active systemic anti-cancer therapy
Palliative care
a. In the past 3 months how many patients were seen who had stage III resectable melanoma
b. Of all stage III patients seen, how many received a complete resection?
c. Of all stage III patients seen, how many were stage III a?
3. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for Non-small cell lung cancer (NSCLC)
Afatinib
Alectinib
Atezolizumab + bevacizumab + carboplatin + paclitaxel
Atezolizumab mono
Bevacizumab
Brigatinib
Ceritinib
Crizotinib
Dacomitinib
Docetaxel monotherapy
Durvalumab
Erlotinib
Gefitinib
Gemcitabine
Necitumumab
Nintedanib with docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab chemo in combination
Pembrolizumab monotherapy
Pemetrexed
Pemetrexed with carboplatin
Pemetrexed with cisplatin
Ramucirumab
Vinorelbine and cisplatin / carboplatin
Other active systemic anti-cancer therapy
Palliative care

Download response Treatment of Lung and Melanoma patients. 221020